Obseva SA (NASDAQ:OBSV) saw a large growth in short interest during the month of November. As of November 29th, there was short interest totalling 464,600 shares, a growth of 9.5% from the November 14th total of 424,300 shares. Approximately 2.4% of the company’s stock are short sold. Based on an average daily volume of 462,300 shares, the short-interest ratio is currently 1.0 days.
NASDAQ OBSV opened at $3.35 on Friday. Obseva has a one year low of $2.37 and a one year high of $15.66. The company has a 50-day simple moving average of $4.67 and a 200-day simple moving average of $8.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.65 and a current ratio of 3.65. The firm has a market capitalization of $154.62 million, a PE ratio of -1.75 and a beta of 0.57.
Obseva (NASDAQ:OBSV) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.19. Equities analysts forecast that Obseva will post -2.6 earnings per share for the current year.
Several research firms have recently commented on OBSV. Zacks Investment Research raised shares of Obseva from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Credit Suisse Group lowered shares of Obseva from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $16.00 to $4.00 in a report on Friday, November 8th. Wedbush reaffirmed a “buy” rating and issued a $38.00 price target on shares of Obseva in a report on Thursday, October 31st. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target (down from $44.00) on shares of Obseva in a report on Monday, December 2nd. Finally, BidaskClub raised shares of Obseva from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $22.00.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More: Why Invest in High-Yield Dividend Stocks?
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.